Delcath Systems, Inc. (DCTH) Q3 Earnings Match Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.02 per share, in line with the Zacks Consensus Estimate . This compares to a loss of $0.03 per share a year ago.
Delcath: Large Upside With Limited Downside Risk
Delcath offers a liver-directed chemotherapy system, which is currently used to treat metastatic uveal melanoma patients. Delcath is facing pricing pressure and slow hospital onboarding at the moment, adding to concerns about the size of the company's addressable market. Recent clinical data support PHP's efficacy in combination with immunotherapies, potentially broadening adoption and addressing market size concerns.
Delcath Systems, Inc. (DCTH) Q2 2025 Earnings Call Transcript
Delcath Systems, Inc. (NASDAQ:DCTH ) Q2 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants David Hoffman - General Counsel, Corporate Secretary & Chief Compliance Officer Gerard J. Michel - CEO & Director Kevin Muir - Corporate Participant Sandra Pennell - Chief Financial Officer Vojislav Vukovic - Chief Medical Officer Conference Call Participants Bill Morgan - Unidentified Company Chase Richard Knickerbocker - Craig-Hallum Capital Group LLC, Research Division I-Eh Jen - Laidlaw & Company (UK) Ltd.
Is the Options Market Predicting a Spike in Delcath Systems Stock?
Investors need to pay close attention to DCTH stock based on the movements in the options market lately.
Delcath Systems: Growing Fast, But Business Model Is Fragile
Delcath's HEPZATO shows rapid sales growth and high pricing, but its efficacy is only moderately better than alternatives and not curative. The addressable market is small, treatment is complex, and future competition from Replimune or Ideaya could threaten long-term prospects and valuation multiples. Financials are solid with no debt, recent profitability, and reasonable stock-based compensation; forward P/S ratio is attractive versus peers.
Delcath Systems, Inc. (DCTH) Is Up 0.62% in One Week: What You Should Know
Does Delcath Systems, Inc. (DCTH) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Predict a 48.69% Upside in Delcath Systems (DCTH): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 48.7% in Delcath Systems (DCTH). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Here's Why Momentum in Delcath Systems (DCTH) Should Keep going
Delcath Systems (DCTH) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Delcath Systems, Inc. (DCTH) Misses Q1 Earnings Estimates
Delcath Systems, Inc. (DCTH) came out with quarterly earnings of $0.03 per share, missing the Zacks Consensus Estimate of $0.10 per share. This compares to loss of $0.43 per share a year ago.
Delcath Systems (DCTH) Soars 9.8%: Is Further Upside Left in the Stock?
Delcath Systems (DCTH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Wall Street Analysts See a 58.49% Upside in Delcath Systems (DCTH): Can the Stock Really Move This High?
The mean of analysts' price targets for Delcath Systems (DCTH) points to a 58.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Is aTyr Pharma (ATYR) Stock Outpacing Its Medical Peers This Year?
Here is how Atyr Pharma (ATYR) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
